22:44:46 EDT Fri 30 Oct 2026
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Ventripoint Diagnostics Ltd (2)
Symbol VPT
Shares Issued 195,579,056
Close 2026-10-30 C$ 0.08
Market Cap C$ 15,646,324
Recent Sedar+ Documents

Ventripoint to seek extension for private placement

2026-10-30 17:02 ET - News Release

Mr. Hugh MacNaught reports

VENTRIPOINT ANNOUNCES EXTENSION OF NON-BROKERED UNIT PRIVATE PLACEMENT

Ventripoint Diagnostics Ltd. will seek approval of TSX Venture Exchange to extend its previously announced non-brokered private placement of up to 3.5 million units at a price of 10 cents per unit. The first tranche of the offering closed on Sept. 8, 2026 (see press release dated Sept. 8, 2026).

Each unit will comprise one common share of the corporation and one common share purchase warrant.

Each whole warrant will entitle the holder thereof to purchase one common share at a price of 14 cents for a period of 24 months from the closing of the offering. The corporation reserves the right to accelerate the warrant expiry period upon 30 days notice if the common shares trade at 30 cents for a period of 10 consecutive days, including days where no trades occur.

The corporation will use the proceeds of the offering to finance commercialization initiatives, advancement of Ventripoint's core diagnostic technology platform and working capital.

All securities issued and issuable pursuant to the offering are subject to a hold period of four months plus one day from the date of closing of the offering. The offering is subject to final approval by the exchange.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS+ products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.

© 2026 Canjex Publishing Ltd. All rights reserved.